Aims: We investigated the patterns of failure and prognostic factors for locoregional control (LRC) in patients with upper urinary tract (UUT) transitional cell carcinoma (TCC) treated with radical surgery to evaluate the role of adjuvant radiotherapy. Materials and Methods: We retrospectively reviewed the medical records of 76 patients with TCC of the renal pelvis and ureter without distant metastasis who underwent curative-intent surgery. No locoregional or distant failure occurred in 19 patients with pTa-1 tumor, and we evaluated patterns of failure and prognostic factors in 57 patients with pT2 or more tumors. Adjuvant chemotherapy was applied in 25 patients. Results: Recurrences occurred in a total of 23 patients, and 20 of these experienced some kind of locoregional failure during follow-up. The overall crude and initial isolated locoregional recurrence rates were 35 and 28%, respectively. In pT2 patients, all 4 recurrences were isolated locoregional recurrences, and 3 of them were successfully salvaged with chemoradiotherapy. Patients with pT3-4 or who were positive for nodal disease (N+) had a lower rate of LRC and worse prognosis after recurrences. On multivariate analysis, incomplete surgery, venous invasion and squamous metaplasia were identified as independent prognostic factors for LRC. Conclusions: Initial loco-regional recurrence was commonly detected by routine computed tomography in locally advanced UUT-TCC. Incomplete surgery, venous invasion and squamous meta-plasia were independently associated with poor LRC. Active postoperative adjuvant treatment such as concurrent chemoradiotherapy could be considered in pT3-4 or N+ patients with adverse risk factors.

Keywords:
Upper urinary tract, Transitional cell carcinoma, Surgery, Chemotherapy, Radiotherapy
1.
Ozsahin M, Zouhair A, Villa S, Storme G, Chauvet B, Taussky D, Gouders D, Ries G, Bontemps P, Coucke PA, Mirimanoff RO: Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre rare cancer network study. Eur J Cancer 1999;35:738-743.
2.
Cozad SC, Smalley SR, Austenfeld M, Noble M, Jennings S, Raymond R: Transitional cell carcinoma of the renal pelvis or ureter: patterns of failure. Urology 1995;46:796-800.
3.
Maulard-Durdux C, Dufour B, Hennequin C, Chretien Y, Vignes B, Droz D, Delanian S, Housset M: Postoperative radiation therapy in 26 patients with invasive transitional cell carcinoma of the upper urinary tract: no impact on survival? J Urol 1996;155:115-117.
4.
Hall MC, Womack JS, Roehrborn CG, Carmody T, Sagalowsky AI: Advanced transitional cell carcinoma of the upper urinary tract: patterns of failure, survival and impact of postoperative adjuvant radiotherapy. J Urol 1998;160:703-706.
5.
Chen B, Zeng ZC, Wang GM, Zhang L, Lin ZM, Sun LA, Zhu TY, Wu LL, Zhang JY, Ji Y: Radiotherapy may improve overall survival of patients with T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse. BMC Cancer 2011;11:297.
6.
Cozad SC, Smalley SR, Austenfeld M, Noble M, Jennings S, Reymond R: Adjuvant radiotherapy in high stage transitional cell carcinoma of the renal pelvis and ureter. Int J Radiat Oncol Biol Phys 1992;24:743-745.
7.
Czito B, Zietman A, Kaufman D, Skowronski U, Shipley W: Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol 2004;172:1271-1275.
8.
Zhang Q, Fu S, Liu T, Peng L, Huang G, Lu JJ: Adjuvant intraoperative electron radiotherapy and external beam radiotherapy for locally advanced transitional cell carcinoma of the ureter. Urol Oncol 2009;27:14-20.
9.
Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG: Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 2009;115:1224-1233.
10.
Kwak C, Lee SE, Jeong IG, Ku JH: Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 2006;68:53-57.
11.
Roupret M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, Babjuk M, Oosterlinck W: European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 2011;59:584-594.
12.
Kim DS, Lee YH, Cho KS, Cho NH, Chung BH, Hong SJ: Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma. Urology 2010;75:328-332.
13.
Bolenz C, Fernandez MI, Trojan L, Herr-mann E, Becker A, Weiss C, Alken P, Strobel P, Michel MS: Lymphovascular invasion and pathologic tumor stage are significant outcome predictors for patients with upper tract urothelial carcinoma. Urology 2008;72:364-369.
14.
Catton CN, Warde P, Gospodarowicz MK, Panzarella T, Catton P, McLean M, Milosevic M: Transitional cell carcinoma of the renal pelvis and ureter: outcome and patterns of relapse in patients treated with postoperative radiation. Urol Oncol 1996;2:171-176.
15.
Domanowska E, Jozwicki W, Domaniewski J, Golda R, Skok Z, Wisniewska H, Sujkow-ska R, Wolski Z, Jozwicka G: Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize. Hum Pathol 2007;38:741-746.
16.
Harnden P, Southgate J: Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas. J Clin Pathol 1997;50:1032-1033.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.